Advertisement

The top ten things that must be known about end of life therapy in patients with advanced cancer

  • Gudrun KreyeEmail author
  • Bettina Heidecker
  • Eva K. Masel
short review

Summary

End of life is an issue that affects every human being sooner or later. Several aspects at the end of life should not be neglected to achieve good symptom control. Basic knowledge and skills on symptom control and palliative care are important to support patients in this threatening phase of their life. Palliative care should not be provided only at the end of life. The concept of early integration of palliative care is increasingly coming into focus. Nevertheless, at the end of life there are some important facts and issues that should be taken into account. This short article provides a list of ten important facts at the end of life that are important for the authors. Prognostication, early integration, benzodiazepines, death rattle, palliative sedation, standard therapy for refractory dyspnea, opioids in renal failure, psylocibin, denial and reduction of drugs at the end of life will be discussed in detail.

Keywords

Early integration Relevant symptoms at the end of life Psychedelic prodrug Medication at the end of life 

Notes

Conflict of interest

G. Kreye, B. Heidecker, and E.K. Masel declare that they have no competing interests.

References

  1. 1.
    Higginson IJ, Gomes B, Calanzani N, Gao W, Bausewein C, Daveson BA, et al. Priorities for treatment, care and information if faced with serious illness: a comparative population-based survey in seven European countries. Palliat Med. 2014;28(2):101–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Sleeman KE, de Brito M, Etkind S, Nkhoma K, Guo P, Higginson IJ, et al. The escalating global burden of serious health-related suffering: projections to 2060 by world regions, age groups, and health conditions. Lancet Glob Health. 2019;7(7):e883–e92.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, Grambow S, Parker J, et al. Preparing for the end of life: preferences of patients, families, physicians, and other care providers. J Pain Symptom Manage. 2001;22(3):727–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003;327(7408):195–8.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Gwilliam B, Keeley V, Todd C, Gittins M, Roberts C, Kelly L, et al. Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ Support Palliat Care. 2015;5(4):390–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Stone P, Gwilliam B, Keeley V, Todd C, Gittins M, Kelly L, et al. Patients’ reports or clinicians’ assessments: which are better for prognosticating? BMJ Support Palliat Care. 2012;2(3):219–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Hui D, Maxwell JP, Paiva CE. Dealing with prognostic uncertainty: the role of prognostic models and websites for patients with advanced cancer. Curr Opin Support Palliat Care. 2019;13(4:360–8.CrossRefGoogle Scholar
  9. 9.
    Sepúlveda C, Marlin A, Yoshida T, Ullrich A. Palliative care: the World Health Organization’s global perspective. J Pain Symptom Manage. 2002;24(2):91–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2017;35(1):96–112.PubMedCrossRefGoogle Scholar
  11. 11.
    Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E, et al. Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol. 2018;19(11):e588–e653.CrossRefGoogle Scholar
  12. 12.
    Vanbutsele G, Van Belle S, Surmont V, De Laat M, Colman R, Eecloo K, et al. The effect of early and systematic integration of palliative care in oncology on quality of life and health care use near the end of life: a randomised controlled trial. Eur J Cancer. 2020;124:186–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Skelton L, Guo P. Evaluating the effects of the pharmacological and nonpharmacological interventions to manage delirium symptoms in palliative care patients: systematic review. Curr Opin Support Palliat Care. 2019;13(4):384–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2016;64(4):705–14.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Gaertner J, Eychmueller S, Leyhe T, Bueche D, Savaskan E, Schlogl M. Benzodiazepines and/or neuroleptics for the treatment of delirium in palliative care?—a critical appraisal of recent randomized controlled trials. Ann Palliat Med. 2019;8(4):504–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Hui D, Frisbee-Hume S, Wilson A, Dibaj SS, Nguyen T, De La Cruz M, et al. Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: a randomized clinical trial. JAMA. 2017;318(11):1047–56.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Lokker ME, van Zuylen L, van der Rijt CC, van der Heide A. Prevalence, impact, and treatment of death rattle: a systematic review. J Pain Symptom Manage. 2014;47(1):105–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Mercadante S, Marinangeli F, Masedu F, Valenti M, Russo D, Ursini L, et al. Hyoscine butylbromide for the management of death rattle: sooner rather than later. J Pain Symptom Manage. 2018;56(6):902–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Cherny NI. Sedation for the care of patients with advanced cancer. Nat Clin Pract Oncol. 2006;3(9):492–500.PubMedCrossRefGoogle Scholar
  20. 20.
    Cherny NI. ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. Ann Oncol. 2014;25(Suppl 3):iii143–iii52.PubMedCrossRefGoogle Scholar
  21. 21.
    Cherny NI, Radbruch L. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med. 2009;23(7):581–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Maltoni M, Scarpi E, Rosati M, Derni S, Fabbri L, Martini F, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol. 2012;30(12):1378–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Hasselaar JG, Reuzel RP, Verhagen SC, de Graeff A, Vissers KC, Crul BJ. Improving prescription in palliative sedation: compliance with dutch guidelines. Arch Intern Med. 2007;167(11):1166–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Reuzel RP, Hasselaar GJ, Vissers KC, van der Wilt GJ, Groenewoud JM, Crul BJ. Inappropriateness of using opioids for end-stage palliative sedation: a Dutch study. Palliat Med. 2008;22(5):641–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Bausewein C, Simon ST, Pralong A, Radbruch L, Nauck F, Voltz R. Palliative care of adult patients with cancer. Dtsch Ärztebl Int. 2015;112(50):863–70.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Simon ST, Koskeroglu P, Bausewein C. Pharmacological therapy of refractory dyspnoea: a systematic literature review. Schmerz. 2012;26(5):515–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Strieder M, Pecherstorfer M, Kreye G. Symptomatic treatment of dyspnea in advanced cancer patients: a narrative review of the current literature. Wien Med Wochenschr. 2018;168(13–14):333–43.PubMedCrossRefGoogle Scholar
  28. 28.
    Simon ST, Higginson IJ, Booth S, Harding R, Weingartner V, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10:Cd7354.PubMedGoogle Scholar
  29. 29.
    Sjogren P, Thunedborg LP, Christrup L, Hansen SH, Franks J. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories. Acta Anaesthesiol Scand. 1998;42(9):1070–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001;69(4):409–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Lee KA, Ganta N, Horton JR, Chai E. Evidence for neurotoxicity due to morphine or hydromorphone use in renal impairment: a systematic review. J Palliat Med. 2016;19(11):1179–87.PubMedCrossRefGoogle Scholar
  32. 32.
    Clemens K, Klaschik E. Morphin und Hydromorphon bei Palliativpatienten mit Niereninsuffizienz. Anästh Intensivmed. 2009;50:70–6.Google Scholar
  33. 33.
    Felden L, Walter C, Harder S, Treede RD, Kayser H, Drover D, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth. 2011;107(3):319–28.PubMedCrossRefGoogle Scholar
  34. 34.
    King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med. 2011;25(5):525–52.PubMedCrossRefGoogle Scholar
  35. 35.
    Douglas C, Murtagh FE, Chambers EJ, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. Palliat Med. 2009;23(2):103–10.PubMedCrossRefGoogle Scholar
  36. 36.
    Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord. 2019;258:11–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–80.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–97.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Nipp RD, El-Jawahri A, Fishbein JN, Eusebio J, Stagl JM, Gallagher ER, et al. The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. Cancer. 2016;122(13):2110–6.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Benkel I, Wijk H, Molander U. Using coping strategies is not denial: helping loved ones adjust to living with a patient with a palliative diagnosis. J Palliat Med. 2010;13(9):1119–23.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Palliative Care Unit, Department of Internal Medicine II, University Hospital KremsKarl Landsteiner University of Health SciencesKrems an der DonauAustria
  2. 2.Campus Benjamin FranklinCharité Universitätsmedizin BerlinBerlinGermany
  3. 3.Clinical Division of Palliative Care, Department of Internal Medicine IMedical University ViennaViennaAustria

Personalised recommendations